Skip to main content

Month: December 2020

Islandsbanki hf.: Útboð á sértryggðum skuldabréfum 3. desember

Íslandsbanki hf. verður með útboð á sértryggðum skuldabréfum fimmtudaginn 3. desember 2020.Boðnir verða út flokkarnir ISLA CB 23, ISLA CB 27 og ISLA CBI 28.Stefnt er að töku skuldabréfanna til viðskipta á Nasdaq Iceland þann 15. desember 2020.Verðbréfamiðlun Íslandsbanka hefur umsjón með útboðinu. Tilboðum skal skilað á tölvupóstfangið vbm@isb.is fyrir kl. 16:00 þann 3. desember 2020.Nánari upplýsingar veita: Fjárfestatengsl ir@islandsbanki.is.

Continue reading

ALSTOM SA: Disclosure of the total number of voting rights and shares forming the share capital as at 30 November 2020

3 December 2020Disclosure of the total number of voting rights and sharesforming the share capital as at 30 November 2020Information pursuant to article L. 233-8 II of the Code de commerce and articles 223-16 and 223-11 of the AMF General regulation (Règlement général de l’Autorité des marchés financiers) Attachment2020.11.30 ALSTOM monthly dec

Continue reading

ALSTOM SA : Déclaration du nombre total de droits de vote et d’actions composant le capital social au 30 novembre 2020

 3 décembre 2020Déclaration du nombre total de droits de vote et d’actionscomposant le capital social au 30 novembre 2020Information prévue par l’article L. 233-8 II du Code de commerce et des articles 223-16 et 223-11 du Règlement général de l’Autorité des marchés financiers : Pièce jointe2020.11.30 ALSTOM decl mensuelle

Continue reading

BlueCity Announces Third Quarter 2020 Unaudited Financial Results

— 47.3% year-over-year revenue growth——43.8% year-over-year total paying user growth—–Reported first quarterly adjusted net income of RMB7.1 million (US$1.0 million)——Completed acquisition of Finka, a leading Chinese gay social networking app —BEIJING, Dec. 02, 2020 (GLOBE NEWSWIRE) — BlueCity Holdings Limited (“BlueCity” or the “Company”) (Nasdaq: BLCT), a leading online LGBTQ platform, today announced its unaudited financial results for the third quarter ended September 30, 2020.Third Quarter 2020 HighlightsTotal revenues reached RMB297.6 million (US$43.8 million), an increase of 47.3% from the same period in 2019.Net loss was RMB137.8 million (US$20.3 million), compared with net loss of RMB7.1 million in the third quarter of 2019.Adjusted Net Income1(Non-GAAP) was RMB7.1 million...

Continue reading

Deep Brain Stimulation Devices Market to Register an Excellent CAGR of 11.6% by 2026; Increasing Prevalence of Neurological Disorders to Accelerate Market Revenue, says Fortune Business Insights™

Pune, India, Dec. 02, 2020 (GLOBE NEWSWIRE) — The global deep brain stimulation devices market size is expected to reach USD 1,676.8 million by 2026, exhibiting a CAGR of 11.6% during the forecast period. The growing awareness among the population concerning various neurological ailments will be a crucial factor in accelerating the deep brain stimulation (DBS) devices market revenue during the forecast period. The market in North America stood at USD 323.4 million in 2018 and is expected to flourish rapidly. The presence of major players in the region will uplift the deep brain stimulation devices market share.INDUSTRY DEVELOPMENTS:February 2019: Medtronic announced the launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy in the U.S. Such novel product launch will assist the company to broaden its customer base...

Continue reading

Sports Medicine Market to Register a CAGR of 5.8% and Hit USD 9.86 billion by 2026; Acquisition of Ivy Sports Medicine by Stryker to Boost Market Expansion, says Fortune Business Insights™

Pune, India, Dec. 02, 2020 (GLOBE NEWSWIRE) — The global sports medicine market size is predicted to USD 9.86 billion by 2026, exhibiting a CAGR of 5.8% during the forecast period. The sports medicine market stood at USD 6.26 billion in 2018. Combined with the market analysis capabilities and knowledge integration with the relevant findings, the report has foretold the robust future growth of the market, and all articulated with geographical and merchandise segments. North America stood at USD 2.60 billion in 2018 and is expected to grow rapidly during the forecast period. The increasing number of medical sports centers will aid the expansion of the market in North America.INDUSTRY DEVELOPMENT:March 2019: Arthrex entered into a partnership with Clemson University, US, with an aim to provide 10 scholarships worth USD 7500 each, for...

Continue reading

iRhythm Technologies Comments on Centers for Medicare and Medicaid Services 2021 Medicare Physician Fee Schedule Final Rule

SAN FRANCISCO, Dec. 02, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, commented on the Centers for Medicare and Medicaid Services (CMS) Calendar Year 2021 Medicare Physician Fee Schedule (MPFS) Final Rule. The Final Rule was announced in a press release on December 1, 2020 and established payment policies, payment rates, and other provisions for services furnished under the MPFS on or after January 1, 2021.The Final Rule describes two new Category I Current Procedural Terminology (“CPT”) code sets related to long term continuous electrocardiogram (“ECG”) monitoring and recording.  Category I CPT codes 93241 – 93248 will replace Category III temporary CPT codes 0295T – 0298T as the primary codes that iRhythm uses to seek...

Continue reading

Skeljungur hf.: Auglýsing vegna yfirtökutilboðs Strengs hf. til hluthafa Skeljungs hf.

Strengur hf. birti auglýsingu í fjölmiðlum í dag, þann 2. desember 2020, þar sem boðað var að tilboðsyfirlit vegna yfirtökutilboðs Strengs hf. til hluthafa Skeljungs hf. yrði birt sunnudaginn 6. desember 2020. Auglýsinguna má finna í viðhengi.Þegar búið er að birta tilboðsyfirlitið mun stjórn Skeljungs hf. semja og gera opinbera sérstaka greinargerð í samræmi við 104. gr. laga nr. 108/2007, um verðbréfaviðskipti.ViðhengiAuglýsing til fjölmiðla – Strengur hf.

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.